Canaccord analyst Jason Mills weighed in today with a favorable report on Sunshine Heart Inc (NASDAQ:SSH), after the company announced that the FDA has approved an …
In a research note published yesterday, Canaccord analyst Jason Mills reiterated a Buy rating on Sunshine Heart (NASDAQ:SSH) with a $10 price target. …
